Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar nassariuscapTA (60.47) Submitted: 7/31/2012 2:06:50 AM : Outperform Start Price: $6.44 EXEL Score: -35.72

pattern out to 8.4

Featured Broker Partners


Advertisement